• Mutational Landscape in Myeloma Cell Lines: Implications for

  2026-05-25

  This article examines a comprehensive exome sequencing analysis of 30 human multiple myeloma cell lines, revealing key mutational drivers and pathways linked to tumor progression and drug resistance. The study provides a foundational resource for selecting myeloma models and designing targeted research, with implications for improving preclinical drug evaluation.

• (+)-Bicuculline: Technical Guidance for GABAA Antagonist Use

  2026-05-24

  (+)-Bicuculline is a classical GABAA receptor antagonist for dissecting inhibitory neurotransmission and synaptic NMDA receptor signaling in neuroscience research. It should be used only in controlled laboratory settings with strict solubilization and storage protocols. This compound is not suitable for diagnostic or clinical applications.

• Fosinopril Sodium: Protocol Enhancements for Hypertension Re

  2026-05-23

  Fosinopril sodium stands out as a phosphinic acid ACE inhibitor with dual renal-hepatic elimination, enabling robust modeling of blood pressure regulation and renal hemodynamics. This article delivers actionable workflows, troubleshooting insights, and practical protocol upgrades for cardiovascular disease models—backed by mechanistic and clinical research.

• RIN3 Mutations, BIN1 Interaction, and RAB5 Hyperactivation i

  2026-05-22

  This study elucidates how mutations in RIN3 that disrupt binding to BIN1 lead to RAB5 hyperactivation and neuronal endosomal pathology, clarifying a mechanistic link between two major Alzheimer’s disease risk genes. The findings provide a foundation for exploring endosomal trafficking as a therapeutic target and highlight the value of precise pathway inhibition in related cellular models.

• CDC42-Polarity Axis Governs Intestinal Stem Cell Fate via YA

  2026-05-22

  Zhang et al. reveal that CDC42-mediated epithelial polarity critically regulates the fate transition from intestinal stem cells (ISCs) to transit amplifying (TA) cells through a Hippo-YAP-EGF-mTOR signaling cascade. This mechanistic insight decouples polarity-dependent fate decisions from canonical Wnt signaling, offering new perspectives for gastrointestinal stem cell biology.

• Phosbind Biotin LC: Sequence-Independent Phosphorylation Det

  2026-05-21

  Phosbind Biotin LC is designed for sensitive detection of phosphorylated proteins on PVDF membranes, providing a sequence-independent alternative to phospho-specific antibodies in Western Blot assays. It should not be used in aqueous-only protocols or for long-term storage of working solutions.

• Fenipentol in Precision Bile Acid Modulation and GI Research

  2026-05-21

  Explore the multifaceted role of Fenipentol (1-Phenyl-1-pentanol) in gastrointestinal physiology studies and bile acid secretion research. This article uniquely analyzes network pharmacology findings and practical assay design using APExBIO’s Fenipentol.

• MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoliu

  2026-05-20

  This article addresses real-world laboratory challenges in cell viability and metabolic activity assays, emphasizing how MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) (SKU B7777) delivers reproducible, quantitative results. By exploring experimental design, protocol optimization, and vendor selection, it demonstrates the value of APExBIO’s high-purity MTT for robust in vitro workflows.

• Ferroptosis Modulation in Translational Oncology: The Role o

  2026-05-20

  Discover how Ferrostatin-1 (Fer-1) is redefining translational research in ferroptosis, bridging mechanistic cellular insights with strategic guidance for oncology-focused investigators. This article incorporates recent findings on multimodal cell death in esophageal squamous cell carcinoma, explains the essential features of Fer-1, and provides actionable advice for deploying selective ferroptosis inhibitors in disease models.

• PA-824: Bicyclic Nitroimidazole Derivative for Tuberculosis

  2026-05-19

  PA-824 is a bicyclic nitroimidazole derivative with potent, verifiable antimycobacterial activity against Mycobacterium tuberculosis. It offers dual-action bactericidal effects, validated efficacy against drug-resistant strains, and robust performance benchmarks. This article delivers atomic, evidence-linked insights for high-fidelity tuberculosis research workflows.

• 28S rRNA Expansion Segments Drive Multilayered Nucleolar Arc

  2026-05-19

  Wei et al. reveal that expansion segments within 28S rRNA mediate multivalent RNA-RNA interactions, enabling the formation of multilayered nucleolar structures. Their work demonstrates that these expansion segments are both necessary and sufficient for complex nucleolar organization and provides mechanistic insight into the evolution of eukaryotic nucleoli.

• EZ Cap™ Firefly Luciferase mRNA (5-moUTP): Benchmarking Biol

  2026-05-18

  Explore the scientific underpinnings of EZ Cap™ Firefly Luciferase mRNA (5-moUTP) as a next-generation bioluminescent reporter. This article uniquely focuses on assay reliability and immunogenicity suppression, leveraging recent advances in mRNA design for enhanced translation efficiency.

• Bortezomib (PS-341): Optimizing Proteasome Inhibition in Can

  2026-05-18

  Bortezomib (PS-341) enables quantitative, reproducible investigation of apoptosis and proteasome-regulated cellular processes in cancer research. Advanced workflows and troubleshooting strategies help researchers maximize data quality and dissect underlying mechanisms, as revealed by cutting-edge studies on drug-induced cell death.

• Optimizing Ceftolozane/Tazobactam Dosing for P. aeruginosa B

  2026-05-17

  This article analyzes a pivotal study on ceftolozane/tazobactam dosing strategies against Pseudomonas aeruginosa bacteremia, emphasizing the pharmacokinetic/pharmacodynamic targets required for optimal bactericidal activity. The findings offer nuanced guidance for tailoring dosing regimens to renal function and infection severity, with direct translational value for experimental and clinical research.

• Applied Use of SAG: Precision Smoothened Receptor Agonist Wo

  2026-05-16

  Smoothened Agonist (SAG) empowers researchers with robust Hedgehog pathway activation in both in vitro and in vivo models, uniquely supporting neuroregeneration, developmental biology, and immune modulation studies. With advanced solubility and validated protocol parameters, SAG from APExBIO streamlines complex research designs and troubleshooting.

451 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page